Clinical Trial

Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated July 17, 2025 (before its estimated June 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
The primary objective of this study is to demonstrate that RAY1225 is superior to placebo for percent change in body weight.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-18.
Status change: Not Yet Recruiting → Recruiting 2025-07-15
Trial Details
NCT Number NCT06893016
Lead Sponsor Guangdong Raynovent Biotech Co., Ltd
Conditions Obesity
Enrollment 640 participants
Start Date 2025-06-15
Primary Completion 2026-06-15 (estimated)
Study Completion 2026-09-15 (estimated)
Updated on ClinicalTrials.gov 2025-07-17